Previous 10 | Next 10 |
2024-05-01 14:38:49 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks are full of intriguing innovators who could help pave the way for greater gains over the years ahead. Undoubtedly, it’s virtually impossible to tell exactly which pill...
2024-04-30 15:03:39 ET Summary The biotech sector has experienced significant volatility but has returned around the same as the risk-free return from the 10-Year Treasury over the past year. There are two key items that will determine the direction of small and midcap biotech sto...
2024-04-27 15:39:17 ET More on Amgen, Cullinan Oncology, etc. Amgen: I Prefer To Chase Value And Dividends Amgen: The Giant With An Impressive Pipeline Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock Cullinan Therapeutics expands into autoim...
2024-04-26 10:26:09 ET More on Gilead Sciences Gilead Sciences, Inc. (GILD) Q1 2024 Earnings Call Transcript Gilead Sciences, Inc. 2024 Q1 - Results - Earnings Call Presentation Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern? Gilead has ...
– Additional Data in Pregnant Adults Who Are Virologically Suppressed Reinforce Safety and Tolerability Profile of Biktarvy in Broad Range of People With HIV – – Perinatal Guidelines Recognize Biktarvy as Alternative Regimen for Use During Pregnancy an...
2024-04-25 21:45:15 ET Image source: The Motley Fool. Gilead Sciences (NASDAQ: GILD) Q1 2024 Earnings Call Apr 25, 2024 , 4:30 p.m. ET Operator Continue reading For further details see: Gilead Sciences (GILD) Q1 2024 Earnings Call Transcript
2024-04-25 20:26:05 ET Gilead Sciences, Inc. (GILD) Q1 2024 Earnings Conference Call April 25, 2024, 04:30 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O'Day - Chairman and Chief Executive Officer Johanna Mercier - Chief Com...
2024-04-25 18:55:25 ET More on Gilead Sciences Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern? Gilead Sciences: Some Signs Of An Impending Bottom Gilead Sciences Finally Starts Succeeding Gilead Sciences Non-GAAP EPS of -$1.32 beats by $...
2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...
2024-04-25 16:19:35 ET More on Gilead Sciences Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern? Gilead Sciences: Some Signs Of An Impending Bottom Gilead Sciences Finally Starts Succeeding Gilead Sciences Q1 Preview: HIV pipeline, FY24 gu...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...